,35 Understanding tumor lipid metabolism and the crosstalk between the lipidome and the pathways that drive HCC has therefore advanced the targeting of lipid pathways in cancer treatments and includes the use of fatty acid synthase (FASN) TVB-2640 for non-small-cell carcinoma (NCT03808558), high-grade sarcoma (NCT03032484), and triple-negative breast cancer (NCT03179904), which are all currently investigated in clinical trials. Here, FASN is linked to neoplasm.